Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Christopher Amen

Physical Medicine & Rehabilitation Smithtown, NY Doctor of Osteopathy

NPI 1205323961 CMS profile 11314730

994 W Jericho Tpke Ste 104, Smithtown, NY 11787

Open in the dashboard

General payments

$23,098

480 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Amen of Smithtown, NY is reported in the CMS Open Payments database as having received $23,098 across 480 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,389 218
2024 General $8,965 215
2023 General $3,084 41
2022 General $660 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Amen
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Christopher Amen were reported at $10,389. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Christopher Amen Physical Medicine & Rehabilitation median Middle half National median
2019 $0 $133 $45–$390 $163
2020 $0 $88 $29–$272 $114
2021 $0 $116 $33–$360 $132
2022 $660 $123 $40–$378 $149
2023 $3,084 $131 $43–$396 $160
2024 $8,965 $141 $45–$409 $164
2025 $10,389 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $6,937 66 payments
  2. Boston Scientific Corporation $2,713 58 payments
  3. Abbott Laboratories $2,531 23 payments
  4. Nalu Medical, Inc. $1,928 15 payments
  5. Relievant Medsystems, Inc. $1,468 10 payments
  6. AbbVie, Inc. $1,204 60 payments
  7. Protega Pharmaceutials LLC $1,011 12 payments
  8. Collegium Pharmaceutical, Inc. $984 104 payments
  9. Nevro Corp. $637 13 payments
  10. Globus Medical, Inc. $362 10 payments
  11. Other $3,322 109 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $14,657 454 payments
  2. Travel and Lodging $5,986 23 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,480 1 payment
  4. Honoraria $525 1 payment
  5. Consulting Fee $450 1 payment
Products named General payments · program years 2022–2025
  1. INTELLIS ADAPTIVESTIM $5,067 27 payments
  2. Nalu Neurostimulation System $1,928 15 payments
  3. Intracept Pain $1,674 14 payments
  4. Intracept Pain $1,468 10 payments
  5. Intracept Pain $1,468 10 payments
  6. Intracept Pain $1,468 10 payments
  7. INCEPTIV $1,234 28 payments
  8. PROCLAIM Neuromodulation $1,101 11 payments
  9. PROCLAIM Structural Heart $995 8 payments
  10. BELBUCA $695 70 payments
  11. Other $10,526 331 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

929

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$86,659

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

24%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 77 $21,238
Belbuca Buprenorphine Hcl Brand 19 $16,014
Oxycontin Oxycodone Hcl Brand 24 $14,997
Xtampza Er Oxycodone Myristate Brand 18 $8,775
Movantik Naloxegol Oxalate Brand 15 $6,789
Celecoxib Generic 176 $5,743
Ztlido Lidocaine Brand 11 $3,743
Pregabalin Generic 56 $2,274
Oxycodone Hcl Generic 123 $1,575
Lidocaine Generic 20 $955

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$604,637

Of which drugs: $3,726

Medicare patients

965

Average age 71

Services billed

7,153

566 women, 399 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 37%
Depression 29%
COPD 27%
Chronic kidney disease 24%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 80 mg J1040 Office 44 49 $376
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 176 222 $64

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $328
$328 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $297
$297 19 —
MOVANTIK
  • Valinor Pharma, LLC $207
$207 15 —
BOTOX
  • AbbVie, Inc. $164
$164 — —
UBRELVY
  • AbbVie, Inc. $152
$152 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

480 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record